Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
Kailera Therapeutics announced participation in upcoming investor conferences.
-
Positive Phase 3 SHIELD II Trial Results - D-PLEX₁₀₀ successfully met its primary efficacy endpoint and demonstrated 58% reduction in SSI NDA submission expected in Q1 2026 Unveiled a Long-Acting...
-
Denver, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Actual Veggies, a CPG leader known for its chef-crafted veggie burgers and vegetable-forward products, has been named to the 2025 Inc. 5000 list of...
-
PolyPid's proprietary and clinically validated, prolonged-release drug delivery technology aims to subcutaneously deliver GLP-1 for approximately 60 days, compared to current standard of care of...
-
Hengrui and Kailera announced positive topline data from Hengrui’s Phase 3 clinical trial of HRS9531, a novel dual GLP-1/GIP receptor agonist, in obesity.
-
NorthStrive Biosciences Announces Initiation of Phase II of Collaboration to Develop AI Powered Therapies for Obesity and Cardiometabolic Diseases
-
Hengrui Pharma and Kailera today announced the presentation of six abstracts at the 85th Scientific Sessions of the American Diabetes Association (ADA).
-
BENGALURU, India, June 10, 2025 (GLOBE NEWSWIRE) -- RenaissThera Private Limited (“RenaissThera”), a Bengaluru-based biotechnology company, announced a major milestone in its obesity drug discovery...
-
BENGALURU, India, June 09, 2025 (GLOBE NEWSWIRE) -- RenaissThera Private Limited (“RenaissThera”), a Bengaluru-based biotechnology company, announced a major milestone in its obesity drug discovery...
-
Kailera Therapeutics today announced the appointments of Adam Koppel and Christopher Hite to its Board of Directors.